Schedule 13D ownership disclosure
Regado Biosciences Inc
Security class unavailable · CUSIP: 75874Q107
Event date: 2016-04-13
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- Unavailable
- Percent of class
- 21.0000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-16-560394
- Form type
- SC 13D
- Filer
- Canticle Pharmaceuticals, Inc.
- CIK
- CIK 1673226
- Filed
- Apr 28, 2016
- Reporting period
- Apr 13, 2016
- Description
- Schedule 13D beneficial ownership